Comparative Pharmacokinetics and Safety of a Micellar Chrysin–Quercetin–Rutin Formulation: A Randomized Crossover Trial
Antioxidants · 31.10.2025 · 14 (11) · 1313
DOI: 10.3390/antiox14111313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 31.10.2025. Verfasst von Afoke Ibi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research, ISURA, Burnaby, BC V3N 4S9, Canada. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chrysin is a dietary flavonoid with antioxidant and anti-inflammatory activity, but its clinical potential is limited by poor oral bioavailability. This randomized double-blind three period crossover trial evaluated the pharmacokinetics of a novel micellar chrysin formulation co-encapsulated with quercetin and rutin (LMC) compared with a non-micellar chrysin formulation (NMC) and unformulated chrysin (UFC). Secondary objectives included in vitro permeability (Caco-2) and a 30-day safety assessment of daily LMC supplementation. Sixteen healthy adults received a single oral dose of each formulation in randomized order separated by a 7-day washout. Plasma chrysin was quantified over 24 h to determine pharmacokinetic parameters. In vitro Caco-2 assays evaluated permeability, and clinical biochemistry of 15 participants were assessed weekly during 30 days of daily LMC use. LMC achieved >2-fold higher systemic exposure than unformulated chrysin (AUC0–24 = 914.8 ± 697.5 ng·h/mL; Cmax = 87.3 ± 59.4 ng/mL; both p < 0.05) and >2.6-fold higher than NMC, supported by >10-fold higher in vitro permeability. Daily LMC supplementation was well tolerated, with only mild, reversible adverse events and no clinically relevant safety changes, despite higher systemic exposure. Small, but significant, reductions in fasting glucose were observed in both sexes. The novel micellar chrysin–quercetin–rutin formulation substantially improved bioavailability and was well tolerated during 30 days of daily use, supporting its potential as an advanced delivery strategy for flavonoids with poor oral absorption and identifying glucose regulation as a physiological effect of interest.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Research, ISURA, Burnaby, BC V3N 4S9, Canada.
- Factors Group R & D, Burnaby, BC V3N 4S9, Canada.
- Academy of Integrative and Holistic Medicine, San Diego, CA 92037, USA.
ORCID-Profile: Chuck Chang, Yun Chai Kuo, Min Du, Julia Solnier
Zitieren
APA
Ibi, A., Chang, C., Kuo, Y. C., Zhang, Y., Do, P., Du, M., Roh, Y. S., Gahler, R., Hardy, M., & Solnier, J. (2025). Comparative Pharmacokinetics and Safety of a Micellar Chrysin–Quercetin–Rutin Formulation: A Randomized Crossover Trial. Antioxidants, 14(11), 1313. https://doi.org/10.3390/antiox14111313
Vancouver
Ibi A, Chang C, Kuo YC, Zhang Y, Do P, Du M, et al. Comparative Pharmacokinetics and Safety of a Micellar Chrysin–Quercetin–Rutin Formulation: A Randomized Crossover Trial. Antioxidants. 2025;14(11):1313. doi:10.3390/antiox14111313
BibTeX
@article{Ibi2025,
author = {Ibi, Afoke and Chang, Chuck and Kuo, Yun Chai and Zhang, Yiming and Do, Peony and Du, Min and Roh, Yoon Seok and Gahler, Roland and Hardy, Mary and Solnier, Julia},
title = {Comparative Pharmacokinetics and Safety of a Micellar Chrysin–Quercetin–Rutin Formulation: A Randomized Crossover Trial},
journal = {Antioxidants},
year = {2025},
volume = {14},
number = {11},
pages = {1313},
doi = {10.3390/antiox14111313}
}
EUVIMED